Figure 5.

LCOs predict dual-targeted therapy for drug-resistant cases

See also Figure S5.

(A) Disease progression of P-60.

(B) Dose-effect curve of LCOs derived from the lymph node (LN) and pericardial effusion of P-60.

(C) FISH of MET amplification of the LN, pericardial effusion, and LCOs derived from pericardial effusion and the LN.

(D) Immunofluorescence staining of MET and DAPI, and immunohistochemistry staining of EGFR L858R for LCOs derived from pericardial effusion and lymph nodes of P-60. Scale bar, 20 μm.

(E) CT scans indicating the progression of the disease of P-60.

(F) Disease progression of P-61.

(G) CT scans of P-61.

(H) FISH of RET rearrangement in pleural effusion (PE) and ascitic effusion (AE)-derived organoids of P-61.

(I) Dose-effect curve of LCOs derived from the PE and AE of P-61.